BACKGROUND: Radiotherapy is the most common curative cancer therapy used for elderly patients with localized prostate cancer. However, the effectiveness of this approach has not been established. The purpose of this study is to evaluate the long-term outcomes of primary radiotherapy compared with conservative management in order to facilitate treatment decisions. METHOD: This population-based study consisted of 57 749 patients with T1-T2 prostate cancers diagnosed during 1992-2007. We utilized an instrumental variable (IV) analytical approach with competing risk models to evaluate the outcomes of primary radiotherapy vs conservative management. The IV was comprised of combined health service areas with high-and low-use areas corresponding to the top and bottom tertile in radiotherapy usage rates. RESULTS: In patients with low-/intermediate-risk prostate cancer, 10-year prostate cancer-specific and overall survival was similar in high-and low-radiotherapy use areas (96.1 vs 95.4% and 56.6 vs 56.3%, respectively). In patients with high-risk disease, however, areas with high-radiotherapy use had a higher 10-year cancer-specific survival (90.2 vs 88.1%, difference 2.1%; 95% CI 0.3-4.0%) and 10-year overall survival (53.3 vs 50.2%, difference 3.1%; 95% CI 1.3-6.3%). Results were similar irrespective of the type of radiotherapy used. To assess the robustness of our choice of IV, we repeated the IV analytical approach using different IVs (using the median utilization rate as the cutoff) and found the results to be similar. CONCLUSIONS: Among men 465 years of age, the benefit of primary radiotherapy for localized disease is largely confined to patients with high-risk prostate cancer (Gleason scores 7-10). 
INTRODUCTION
Prostate cancer is the most common nonskin cancer and the second most common cause of cancer death in men, striking~1 out of every 6 American men during his lifetime. 1 The majority of men (over 90%) are diagnosed at localized stages (T1 or T2) 2 and standard treatments include radiotherapy, surgery or conservative management. 3 For men o 65 years of age with clinically localized prostate cancer, results of a large, randomized clinical trial have demonstrated that surgery improves survival compared with conservative management. 4, 5 The majority of men diagnosed with localized prostate cancer, however, are over the age of 65 years. Although not specifically designed to address age effects, this same clinical trial 4, 5 was unable to demonstrate a survival benefit for surgery among older men. 6 Although radiotherapy represents the most common form of curative treatment for elderly patients, 7 long-term outcomes data following radiotherapy are sparse and a comprehensive review concluded that data are 'insufficient' to support the use of radiotherapy in early stage prostate cancer. 8 In the absence of data from randomized clinical trials, instrumental variable analysis (IVA) has been used to minimize biases in observational studies [9] [10] [11] and produce results similar to randomized clinical trials. 12 Our previous study has shown that there are substantial geographic variations in the use of prostate cancer therapies and that clinical factors have a limited role in treatment selection among elderly patients with localized prostate cancer. 13 These data suggest that IVA may be appropriate for evaluating prostate cancer therapies.
The major advantage of IVA is its ability to capture the random component of treatment choice (for example, some patients in a geographic area will receive radiotherapy solely by chance because it is more popular or easily available in that area) and use it to balance both measured and unmeasured confounding factors. This study aims to address the long-term outcomes of primary radiotherapy vs conservative management among patients over age 65-years old with localized prostate cancer.
MATERIALS AND METHODS

Data
Data were derived from the US Surveillance, Epidemiology and End Results (SEER) 14 and linked Medicare claims files. The SEER program captures 98% of all cancer cases in designated geographical regions. 15 Medicare provides health insurance for people aged 65 and over in the United States. Medicare part A covers hospital, nursing home and home health care, and part B covers physician and outpatient care. To create the SEER Medicare-linked database, each SEER registry provides information on each person diagnosed as having cancer in its area. A deterministic matching algorithm was used to link SEER data with Medicare claims files. 15 To ensure confidentiality, unique identifiers are assigned. Linkage of the two databases was~93%. 15 Participants Inclusion criteria for the study are as follow: (1 Exclusion criteria for the study are as follows:
(1) Having other cancers (n = 19 695) or metastatic disease within 6 months of diagnosis (n = 1882). (2) Having palliative radiation (n = 2550), cryotherapy (n = 1015), prostatectomy (n = 16 246), primary androgen deprivation therapy (ADT) without radiotherapy (n = 11 387), radioisotope treatment (n = 181) within 12 months of diagnosis. (3) Having missing data on health service area, cancer stage or grade (n = 4568).
Identification of radiotherapy, androgen deprivation therapy and conservative management A previously described algorithm with minor modification was used to identify use of radiotherapy, 16 orchiectomy and luteinizing hormone releasing hormone agonists. 17 Primary radiotherapy was defined as therapy received within 1 year of diagnosis. Brachytherapy, external beam radiotherapy and combinations of the two were included in the radiation treatment group. External beam radiation therapy included three-dimensional conformal radiotherapy, intensity-modulated radiation therapy or proton beam therapy (Table 1) . Conservative management was defined as being free of surgery, radiotherapy, cryotherapy or primary ADT for at least 12 months after diagnosis.
Study end points and covariates Vital status and underlying cause of death were derived from the SEER data (~88% agreement compared with medical records). 18 Before 2003, the SEER database grouped Gleason scores 5-7 together and these patients were included in the low-/intermediate-grade group for this study. Starting in 2003, Gleason 7-10 diseases constituted the high-grade category in the SEER, whereas Gleason 2-6 cancers were in the low-/intermediate-grade category. The Charlson score, a validated predictor of longevity in localized prostate cancer, was derived from Medicare inpatient, outpatient and physician claims during the year before diagnosis using a validated algorithm. 19 Instrumental variable analysis To construct the instrumental variables, we first calculated the proportion of eligible patients receiving radiotherapy in each health service area (HSA), defined as one or more counties that are relatively self-contained with respect to the provision of routine hospital care. 20 Each HSA with o50 eligible patients was combined with the nearest (in terms of distance between geographic centers) HSA until it reached 50 cases because lower thresholds were associated with unstable estimates. Radiotherapy utilization for low-/intermediate-risk and high-risk groups was calculated separately so that it was not necessary to assume that the patterns of radiotherapy utilization were the same for all risk levels within the same HSA area. We have divided the continuous predictor (radiotherapy utilization rate) into two distinct categories, as discussed in the IVA context by Angrist, Imbrens, and Rubin. 21 High-and low-use areas corresponded to the top and bottom tertiles of radiotherapy utilization, and were chosen to provide sufficient differences in utilization and sample size. We also used median utilization rate as the cutoff in the sensitivity analysis ( For the IVAs, our models included age, race, education quartile, income quartile, urban residence, co-morbidity status, marital status, state buy-in (poverty) status, cancer stage, use of ADT within the first year of diagnosis and year of diagnosis. Cancer grade was included in the models that included all localized prostate cancer. The treatment and region variables were replaced by a single covariate indicating high-or low-radiotherapy utilization (the instrumental variable). Patients in regions with utilization rates in the middle tertile were not included in the main IV analysis. To account for variability in hazard rates among the HSAs, we included a normally distributed random effects term, known as a 'frailty,' and implemented it using the 'coxme' package in the R statistical package. [21] [22] [23] We compared high-and low-use areas by estimating the hazard ratios and differences in 10-year survival rates for this covariate-adjusted frailty model.
We computed adjusted bootstrap confidence intervals (CI) for the 10-year fitted survival rates as follows. First, we computed, for each patient, and for each bootstrap sample, the predicted covariate-adjusted 10-year survival under two alternatives: that the patient was in a high-use area and that the patient was in a low-use area. All patients, including those in the middle tertile, could thus be included in the bootstrap analysis. The populationadjusted survival rates in high-and low-use areas were obtained by averaging these rates across the population. 24 Mean and CIs of the mean were then computed from 1000 bootstrap samples. 25 We computed the cumulative incidence probabilities of death because of prostate cancer by treating other causes of death as competing risks. The proportional hazards assumptions were checked using log-log plots and the Schoenfeld residuals test 24 and found to be satisfactory.
All the subgroup analyses (by cancer grade) were pre-specified. There was 80% power to detect a 15% relative difference in disease-specific hazard rate for the low-grade group. In sensitivity analyses, we used a different IV, using the median radiotherapy utilization rate as the cutoff and included all patients in the analysis (Table 5) . We also limited the analysis to patients with Gleason score 8-10 cancer to assess the outcomes with and without Gleason score 7 cancer.
RESULTS
Baseline characteristics
There were 57 749 eligible men aged ⩾ 66 years with localized prostate cancer diagnosed during 1992-2007 (Table 1) . Median age at diagnosis was 74 years and median follow-up for overall survival was 130 months (interquartile range, 91-177 months). Concurrent or adjuvant ADT use in the first year of cancer diagnosis was common (41%) in patients receiving primary radiotherapy.
Patients treated with radiotherapy were younger and healthier than those receiving conservative management (Table 1) , suggesting that conventional analytic methods would likely be subject to bias. Following the application of IVA, however, clinical characteristics (for example, age, Charlson score, PSA, Gleason score or use of ADT in the first year of diagnosis) were similar in areas with high-and low-radiotherapy use, suggesting that IVA was effective in reducing biases (Table 2) . Survival There were 3120 prostate cancer deaths and 28 733 all-cause deaths. In patients with low/intermediate disease, 10-year prostate cancer-specific was similar in high-and low-use areas (96.1% (high-use) vs 95.4% (low-use), difference 0.7; 95% CI = − 0.1 to 1.2%), as was 10-year overall survival (56.6% (high use) vs 56.3% (low-use), difference 0.3%; 95% CI = − 1.7 to 0.3%). In patients with high-risk disease, areas with high-radiotherapy use had higher 10-year cancer-specific survival (90.2% vs 88.1%, difference 2.1%; 95% CI = 0.3-4.0%) and 10-year overall survival (53.3 vs 50.2%, difference 3.1%; 95% CI = 1.3-6.3%). (Table 3 and Figure 1a and b). Table 4 presents hazard ratios (HRs) derived from Cox models as well as IVA models, in order to contrast our data with the existing literature (which typically uses Cox models). When conventional Cox models were employed, radiotherapy was associated with 46% reduction in prostate cancer-specific mortality (HR = 0.54; 95% CI = 0.49-0.59) and 36% in overall mortality (HR = 0.64; 95% CI = 0.62-0.66). Outcomes were similar irrespective of the type of radiotherapy used (Figure 2) .
To assess the effect of grouping Gleason 7 with 8-10 in the high-risk patients, we restricted the analyses to men with Gleason scores 8-10 disease. The resulting hazard ratios (radiotherapy/ conservative management) changed only slightly, from 0.79 (95% CI 0.65-0.93) to 0.75 (95% CI 0.59-0.93). To assess the robustness of our choice of IV, we repeated the IVA approach using different IVs (using the median utilization rate as the cutoff). The conclusion was the same when median utilization of radiotherapy was used as the cutoff for IV construction (Table 5) .
DISCUSSION
Prostate cancer treatment should rely on a thorough understanding of potential outcomes following interventions. However, to date, there are no published randomized data that adequately compare radiotherapy vs conservative management for localized prostate cancer. Our study attempted to take a significant step toward filling this gap.
Our results based on IV analysis show that the potential survival benefit associated with radiotherapy was largely limited to patients with high-grade prostate cancer (Tables 3-5) and that the effects of different radiotherapy modalities were similar (Figure 2) . These results are consistent with those of randomized trials and clinical guidelines. Radiation Therapy Oncology Group's trial 7706 showed that prophylactic radiation therapy to clinically or pathologically uninvolved pelvic lymph nodes does not appear to improve overall or prostate cancer-specific survival. 26 Because there are no published randomized trials comparing radiotherapy vs conservative management for T1/T2 prostate cancer, we sought to compare our results with findings of the Prostate Cancer Intervention versus Observation Trial 27 and the Scandinavian Prostate Cancer Group 7 Prostate Cancer Intervention versus Observation Trial. 28 PIVOT 27 compared the outcomes of radical prostatectomy vs observation while Scandinavian Prostate Cancer Group 7 compared endocrine treatment with or without radiotherapy for T3 prostate cancer. 28 Our results, based on IVA analyses, are similar to the results of these two trials, in which a survival benefit was limited to patients with high-risk features. 27, 28 The borderline survival benefit observed in the low-/intermediate-grade group in this study is also consistent with the results our earlier study, 29 which showed that patients with low-grade disease have 10-year relative survivals exceeding or approaching age-matched cohorts, thus making an improvement in survival highly unlikely. 29 In contrast, 10-year relative survival compared with age-matched men was only 0.63 29 in patients with high-grade disease (Gleason 8-10), and effective intervention may make a clinically meaningful difference in these patients. 29 Radiotherapy with adjuvant ADT has been shown to improve survival for patients with high-risk prostate cancer 30 and has been recommended as the initial therapy in, for example, the National Cancer Center Network Guideline. 31 Notably, the results of our conventional Cox multivariate analyses (Table 4) for cancer-specific survival (HR 0.54 in favor of radiotherapy, 95% CI 0.49-0.59) was lower than those of three previously published studies [32] [33] [34] included in the comprehensive Agency for Healthcare Research and Quality review of radiotherapy in localized prostate cancer 8 (HRs of 0.64-0.67 in favor of radiotherapy) and the study by Abdollah et al., 35 who used propensity-score matching analytical approach. Our overall survival results utilizing conventional Cox analyses (HR 0.64 in favor of radiotherapy, 95% CI 0.62-0.66) replicated those reported in the Agency for Healthcare Research and Quality assessment (HRs of 0.63-0.70). 8 These results suggest that our findings based on conventional Cox regression might have been subject to similar biases as those in the literature.
Despite the notable finding that radiotherapy benefit is limited to high-risk disease, one potential limitation of the study was that the SEER-Medicare database did not capture PSA and detailed Gleason score information for patients diagnosed before 2004, so patients with Gleason 7 disease before 2003 were included in the low-/intermediate-risk group. Our inclusion of some Gleason grade 7 patients in the low/intermediate group might lead to overestimation of radiotherapy benefit in the low-risk category (although little benefit has been shown). Although we could not separate out Gleason 7 among those diagnosed before 2003, limiting the analyses to men with only Gleason scores 8-10 yielded similar results, suggesting that patients with Gleason score 7 might experience a similar survival improvement as those with Gleason score [8] [9] [10] .
A challenge associated with prostate cancer research is that methods of treatment often change quickly, whereas data to support the use of various therapies matures slowly because of the long natural history of the disease. For example, during the study period, various radiotherapy modalities were used, potentially making the assessment of radiotherapy efficacy a moving target. 36 Nonetheless, analysis by type of radiotherapy revealed consistent results within the low-/intermediate-and high-grade groups (Figure 2 ). Adjusted prostate cancer-specific survival rate difference at 10 years by treatment. The midpoint of the box represents the point effect estimate, that is, the adjusted population average cancer-specific difference at 10 year between high-and low-radiation use area. The area of the box represents the sample size of each treatment group. The larger box size represents the larger sample size. The width of the line shows the 95% confidence intervals of the effect estimate of individual treatment. The 95% confidence interval was computed from 1000 bootstrap samples. The arrow showed the lower and upper limits for clipping confidence intervals. External beam radiation therapy included three-dimensional conformal radiotherapy, intensity-modulated radiation therapy, proton beam therapy or unknown type therapy. The result of three-dimensional conformal radiotherapy was similar to that of external beam radiation.
The primary limitation of utilizing an administrative database is the lack of detailed clinical information, which should be largely compensated for by the IVA approach. However, in spite of the ability to balance potential risk factors through IVA and to include relevant risk factors such as age, race, education, income and marital status in the models, it is possible that residual imbalances in both measured and unmeasured confounding variables can persist, as they sometimes do even in randomized clinical trials. Therefore, other authors' confirmation of our findings would certainly provide greater confidence in our results. Finally, this study focused on men aged 65 and over and therefore the results might not be applicable to younger men. In contrast to the study's potential limitations, there were also important strengths. The statistical method employed allowed us to minimize bias, and because the study was population-based and included all patients in the relevant geographic areas rather than a select group of patients common to an institution or network, the results are more likely to be broadly applicable. Although we did exclude patients for incomplete treatment records, most clinically relevant exclusions were for patients treated with other modalities (for example, primary androgen deprivation, cryotherapy, surgery and so on), and the eligible population was far more extensive than is typical of clinical trials, implying that the results may be more generalizable. Also, the large sample size of 57 749 patients provided more statistical certainty than has been typical of previous studies. Finally, the IVA-based approach appears robust, illustrated by the similar results obtained when grouping HSAs by either tertiles or into two groups by median radiation utilization ( Table 5) .
As a consequence of cancer screening and an increasingly aged population, the number of men with localized prostate cancer will increase dramatically in the coming decades. How radiotherapy is utilized may impact the quality of life of millions of men and significantly affect patients' and society's overall health-care costs. Complications related to sexual, urinary, and bowel function following radiotherapy can be substantial and long lasting. 37, 38 Given the far-reaching impact of radiotherapy-related complications and the differences in impact on survival according to disease risk, a careful assessment of the potential risks, benefits and costs of different therapies for localized prostate cancer should be carefully reviewed before making treatment decisions.
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b High-and low-use areas corresponded to the top tertile and bottom tertiles of radiotherapy utilization.
c High-and low-use areas corresponded to the above median and below median of radiotherapy utilization.
d In order to calculate prostate cancer-specific survival, death because of other cause was treated as a competing risk.
